Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRSD107 versus enoxaparin for venous thromboembolism prevention after total knee arthroplasty
2024-519688-16-00Phase 2Authorised
- Sponsor
- Sirius Therapeutics
- Start
- Aug 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of SRSD107 in venous thromboembolism (VTE) (2 arms), sponsored by Sirius Therapeutics. Primary endpoint: Incidence of total venous thromboembolism events. Planned start Aug 2025; status: authorised.
02
Drugs
SRSD107
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2024-519688-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519688-16-00.